DOCSLIB.ORG

Other Review(S)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Other Review(S) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761122Orig1s000 OTHER REVIEW(S) Center for Drug Evaluation and Research Office of Pharmaceutical Quality Office of Biotechnology Products LABELS AND LABELING ASSESSMENT Date of assessment: May 16, 2019 Assessor: Scott Dallas, RPh, Labeling Assessor Office of Biotechnology Products (OBP) Through: Lymarie Maldonado-Baez, PhD, Product Quality Reviewer OBP/Division of Biotechnology Review and Research I Application: BLA 761122 Applicant: GlaxoSmithKline LLC Submission Date: August 7, 2018; February 28, April 18 and May 9, 2019 Product: Nucala (mepolizumab) Dosage forms: Injection Strength and 100 mg/mL, single-dose prefilled autoinjector or single-dose prefilled Container-Closure: syringe (proposed under BLA 761122) Purpose of The Applicant submitted a biologics license application for a liquid assessment: formulation of Nucala (mepolizumab) to be administered subcutaneously via an autoinjector or a safety syringe device. Recommendations: The prescribing information, patient information, instructions for use, container labels, and carton labeling are acceptable from an OBP labeling perspective. Materials Considered for this Label and Labeling Assessment Materials Assessed Appendix Section Proposed Labels and Labeling A Evaluation Tables B Acceptable Labels and Labeling C DISCUSSION We evaluated the proposed labels and labeling for compliance with applicable requirements in the Code of Federal Regulations (see Appendix B). Please note the Prescribing Information for this BLA is to be combined with the approved labeling for BLA 125526 Nucala (mepolizumab) for injection, 100 mg/vial, approved on November 4, 2015. CONCLUSION The prescribing information, patient information, instructions for use, container labels, and carton labeling submitted on April 18 and May 9, 2019 were assessed and found to be acceptable (see Appendix C) from an OBP labeling perspective. Page 1 of 9 APPENDICES Appendix A: Proposed Labeling Prescribing Information and Patient Information (submitted on August 7, 2018) \\cdsesub1\evsprod\bla761122\0001\m1\us\114-labeling\1141-draft\draft-annotated.pdf Instructions for Use - Autoinjector (submitted on August 7, 2018) \\cdsesub1\evsprod\bla761122\0001\m1\us\114-labeling\1141-draft\draft-auto-ifu- 100mg.pdf Instructions for Use - Syringe (submitted on August 7, 2018) \\cdsesub1\evsprod\bla761122\0001\m1\us\114-labeling\1141-draft\draft-syr-ifu- 100mg.pdf (b) (4) 2 Pages of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page Page 2 of 29 Appendix B: Evaluation Tables Evaluation Tables: Label1·2 and Labeling3 Standards Container4 Label Evaluation Commercial and Sample Container Labels Proner Name (for container ofa product capable of bearino a full label) Accentable 21 CFR 610.60, 21 CFR 201.50, 21 CFR 201.10 ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - acceptable Syrinae- acceptable Recommended labeling practices (placement of dosage form below the proper ./Yes name) : D No D N/A Comment/ Recommendation: Autoinjector - acceptable Syrinae - acceptable Manufacturer name, address, and license number Acceptable (for container ofa oroduct caoable of bearino a full label) 21CFR610.60 (a)(2), 21 CFR 201, 21CFR201. l(a), 21 CFR 201.l(h)(S), 21 ./ Yes CFR 201.1(h)(6), 21 CFR 201.lOO(e) D No D N/A Comment/ Recommendation: Autoinjector - acceptable, but no license number which is acceptable because it's a partial label Syringe - acceptable, but no license number which is acceptable because it's a partial label Recommended labeling practices (using the following qualifying statement D Yes "Manufactured by: NJ: D No 1:81 N/ A Comment/ Recommendation: Autoinjector -NA it's a partial label Syringe - NA it's a partial label 1 Per 21 CFR 1.3(b) Label means any display of written, printed, o r graphic matter on the immediat e container of any article, or any such matter affixed to a ny consumer commodity or affixed to or appearing upon a package containing any consumer commodity. 2 Per CFR 600.3(dd) Label means any writte n, printed, or graphic matter on t he container or package or any such matter clearly visible t hrough t he immediate carton, receptacle, or wrapper. 3 Per 21 CFR 1.3(a) Labeling includes all writte n, printed, or graphic matte r accompanying an article at any t ime while such article is in interstate commerce or held for sale after shipment or delivery in interstate commerce. 4 Per 21 CFR 600.3(bb) Container (referred to a lso as "final container") is t he immediat e unit, bott le, vial, ampule, tube, or other receptacle containing t he product as distributed for sale, barter, o r exchange. Page 5 of 29 Lot number or other lot identification Acceptable (container capable of bearing a full label shall bear) 21CFR610.60, 21 CFR201.18, 21CFR201.100 ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - Please verify the lot number will be provided on t he label per 21 CFR 610.60(a)(3) and indicate where this information will appear. Syringe- acceptable April 18, 2019: The revised autoinjector container labels include the words "Lot" and "Exp", and GSK confirmed t his information will appear on t he label. FDA response: GSK's revisions are acceptable. Exniration date fcontainer capable ofbearino a full label shall bear) Accentable 21CFR610.60, 21 CFR201.17 ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - Please verify the expiration date will be provided on t he label per 21 CFR 610.60(a)(4) and indicate where this information will appear. Syringe - acceptable April 18, 2019: The revised autoinj ector container labels include the words " Lot" and "Exp", and GSK confirmed t his information will appear on t he label. FDA response: GSK's revisions are acceptable. Recommended labeling practices (the expiration date appears on all aspects of o Yes the package): o No l:8J N/A Product Strennth Accentable 21 CFR 201.lO(d)(l), 21 CFR 201.100(b)(4) ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - acceptable Svrinae - acceptable Recommended labeling practices (expression of strength for injectable drugs): Reference: Draft Guidance Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Error~ April 2013 line176 USP General Chapters: <7> Labelino Autoinjector - acceptable ./ Yes D No Syringe - acceptable D N/A Page 6 of 29 AcceRtable MultiRle dose containers {recommended individual dose} 21 CFR 610.60, 21 CFR 201.55 D Yes D No l&1 N/A Statement: "Rx onlv" Accentable 21 CFR 610.60, 21 CFR 201. 100 D Yes D No l&1 N/A Comment/ Recommendation: Autoinjector - no Rx only statement, but it's acceptable, because it can be considered a partial label Syringe- no Rx only statement, but it's acceptable, because it can be considered a partial label Recommended labeling practices : D Yes D No l&1 N/ A Medication Guide Accentable 21 CFR 610.60, 21 CFR 208.24 D Yes D No l&1 N/A No Packane for container Accentable 21 CFR 610.60 D Yes D No l&1 N/A Recommended labeling practices : D Yes (U.S license number for container bearing a partial label) D No l&1 N/A Comment/Recommendation: Dartial label No container label Accentable 21 CFR 610.60 D Yes D No l&1 N/A Comment/ Recommendation: Autoinjector - ok, it has a carton Svrinae - ok it has a carton Ferrule and can oversea! (for vials onlvJ Accentable Recommended labeling practices: D Yes United States Pharmacopeia (USP)/ General Chapters: <7> Labeling (Ferrules D No and Cap Overseals) l&1 N/A Page 7 of 29 Visual insnection ffor vials on/vJ Accentable 21 CFR 610.GO(e) ./ Yes D No D N/A Comment/ Recommendation: Autoinjector and Syringe - provide an inspection window NOC numbers Accentable 21 CFR 201.2, 21 CFR 207.35 ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - acceptable, has a NDC Syringe- acceptable, does not contain a NDC, but it is a partial label Route of administration Accentable 21 CFR 201.5, 21 CFR201. 100 ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - acceptable Syringe- acceptable, does not contain a ROA, but it is a partial label Recommended labeling practices : D Yes route of administration statement to appear after the strength statement on D No the principal display panel l:8J N/A Comment/ Recommendation: Autoinjector - space/design does not permit this format Syringe- NA, partial label Prenaration instructions Accentable 21CFR201.5 D Yes D No l:8J N/A Comment/ Recommendation: Autoinjector - not required partial label Syringe - not required partial label Page 8 of 29 Recommended labeling practices : D Yes Draft Guidance Safety Considerations for Container Labels and Carton Labeling D No Design to Minimize Medication Errors, April 2013 (lines 426-430) l&1 N/A Please note OPDP recommended removal of the partial instruction graphics on the container label. Package :W~ term AcceRtable Recommended labeling practices: Guidance for Industry: Selection of the ./ Yes Appropriate Package Type Terms and Recommendations for Labeling D No Injectable Medical Products Packaged in Multiple-Dose/ Single-Dose/ and D N/A Single-Patient-Use Containers for Human Use. USP chapter <659> Packaging and Storage Requirements I Comment/ Recommendation: Autoinjector -acceptable Svrinae- not reauired partial label Misleadina statements Accentable 21CFR201.6 D Yes D No l&1 N/A Comment/ Recommendation: Autoinjector -NA Svrinae- NA Prominence of r~uired label statements Accentable 21 CFR 201.15 ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - acceptable Syringe- acceptable Snanish-lanauaae lDruasl Accentable 21 CFR 201.16 D Yes D No l&1 N/A FD&C Yellow No. 5 and/or FD&C Yellow No. 6 Accentable 21 CFR 201.20 D Yes D No l&1 N/A Phenvlalanine as a comnonent of asnartame Accentable 21 CFR 201.21 D Yes D No l&1 N/A Page 9 of 29 Sulfites~ renuired warninn statements Accentable 21 CFR 201.22 D Yes D No l:8J N/A Bar code label renuirements Accentable 21 CFR 201.25, 21 CFR 610.67 ./ Yes D No D N/A Comment/ Recommendation: Autoinjector - acceptable Note: The sample autoinj ector label does not contain a linear bar code.
Load more

Recommended publications
  • Sodium Chloride Injection USP 0.9% Prefilled Syringes, for Intravascular Use Only ------WARNINGS and PRECAUTIONS ------Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------- DOSAGE FORMS AND STRENGTHS --------------------- These highlights do not include all the information needed to use • Supplied as a clear, colorless, odorless, sterile solution of Sodium Sodium Chloride Injection USP 0.9% safely and effectively. See Chloride 0.9% for intravenous administration (3) full prescribing information for Sodium Chloride Injection USP • Supplied in 50 mL and 125 mL prefilled syringes (3) 0.9%. ------------------------------- CONTRAINDICATIONS ------------------------------- • None (4) Sodium Chloride Injection USP 0.9% Prefilled Syringes, For Intravascular Use Only ----------------------- WARNINGS AND PRECAUTIONS ----------------------- Initial U.S. Approval: 2006 • Remove all air from the syringe and associated tubing prior to injection. (5.1) ----------------------------INDICATIONS AND USAGE ---------------------------- • For use in flushing compatible contrast agents through Liebel- • May cause fluid overload in patients with congestive heart failure, Flarsheim intravenous administration sets into indwelling severe renal insufficiency, and in clinical states with edema, sodium retention, or hypernatremia. (5.3) intravascular access devices (1) • Establish intravascular catheter patency prior to administration. ----------------------- DOSAGE AND ADMINISTRATION ----------------------- (5.4) • For single patient use only. (2) • Determine the volume of flush based on the imaging procedure, ------------------------------ ADVERSE REACTIONS ------------------------------
    [Show full text]
  • Migraine Specialty Care Program Tm
    MIGRAINE SPECIALTY CARE PROGRAM TM Phone: 833-796-6470 • Fax: 844-841-3401 Community Led Specialty Pharmacy Care 1 PATIENT INFORMATION: 2 PRESCRIBER INFORMATION: Name: ___________________________________________________ Name: ___________________________________________________ Address: _________________________________________________ Address: _________________________________________________ City: _________________________ State: ____ Zip: ____________ City: _________________________ State: ____ Zip: ____________ Phone: ___________________ Alt. Phone: ____________________ Phone: _____________________ Fax: _______________________ Email: ____________________________________________________ NPI: ________________________ DEA: _______________________ DOB: ___________ Gender: M F Caregiver: _____________ Tax I.D.: __________________________________________________ Height: ________ Weight: ________ Allergies: ________________ Office Contact: __________________ Phone: __________________ 3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation) Prior Failed Indicate Drug Name v10.0_060821 Length of Symptoms: ___________________________ ICD-10: _________________________ Treatments: and Length of Treatment: Other diagnosis _______________ Number of Migraine Days per month: ________________ Preventative: Headache Days per month: _________________ Migraine Hours per day: __________________ ACE-I/ARBs ___________________ Patient has been evaluated and does not have medication overuse headache? No Yes Antiepileptics ___________________
    [Show full text]
  • DDT Cover/Back April 2006.Qx
    March 2007 Vol 7 No 3 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH DPT’S PRESIDENT MR. PAUL JOHNSON In Situ Gel Systems 30 Mitan Gokulgandhi, BPharm Dharmesh M. Modi, MPharm COX-II Microspheres 38 Lakshmi Sivasubramanian Madhumathi Seshadri Undermining CEO’s 82 John A. Bermingham FEATURING Parkinson’s Disease 59 Steven Damon Yogi R. Patel The science & business of specialty pharma, biotechnology, and drug delivery Specialty Pharma Indices 64 Dr. Barath Christopher Avani Amin, Josef Bossart, PhD Shankar Robinson, PhD Drug Delivery’s PhD Current Status of Clinical Trials Increasing New Ways to Non-Invasive In Asia 68 Importance to Partner With Insulin Delivery Ames Gross, MBA Big Pharma & the Federal Technologies Specialty Pharma Government Momoko Hirose March 2007 Vol 7 No 3 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren
    [Show full text]
  • Medication Permission Form
    CHARDON LOCAL SCHOOLS MEDICATION PERMISSION FORM Student Name :__________________________________________ Grade/Class _______ Teacher :______________________ School ____________________ Student Address:____________________________________________________________________________ Date of Birth____________________________ TO BE COMPLETED BY HEALTH CARE PROVIDER Please print clearly and complete ALL sections. Time/Frequency Adverse Reaction to Report to (Include minimum time Physician and/or Special Name of Medication Dose Route (circle) Interval for prn dosing) Reason for Medication Start Date Stop Date Instructions Tablet/Capsule PO Liquid PO _________________ __/__/__ ___/___/___ Inhaler/Nebulizer OR OR Other__________ As needed every __hrs. ___ End of School year Tablet/Capsule PO Liquid PO _________________ __/__/__ ___/___/___ Inhaler/Nebulizer OR OR Other__________ As needed every __hrs ___ End of School year EPINEPHRINE AUTOINJECTOR Not Applicable SELF -CARRY AUTHORIZATION Yes, as the prescriber I have determined that this student is capable of possessing and using this autoinjector appropriately and have provided the student with training in the proper use of the autoinjector. ASTHMA INHALER Not Applicable SELF -CARRY AUTHORIZATION Yes, as the prescriber I have determined that this student to capable of possessing and using this inhaler appropriately and have provided the student with training in the proper use of the inhaler. Reminder note for prescriber: ORC 3313.718 requires backup epinephrine autoinjector and best practice recommends backup asthma inhaler Health Care Provider Name _______________________________________ Health Care Provider Signature: ______________________________________ Date_________________ Phone Number: _______________________________________ Fax Number: _________________________________________ TO BE COMPLETED BY PARENT OR GUARDIAN I authorize an employee of the school board to administer the above medication. I understand that additional parent/prescriber signed statements will be necessary if the dosage of medication is changed.
    [Show full text]
  • Aerogen Nebulizer)
    Page 1 of Date of Original: 11/15/18 Date of Review: Date of Revision: 9/4/19 Respiratory Therapy POLICY & PROCEDURE MANUAL RIBAVIRIN ADMINISTRATION (Aerogen nebulizer) PURPOSE: 1. Standardize the administration and delivery of ribavirin by aerosol 2. To protect the patient and caregivers by standardizing precautions for ribavirin delivery POLICY: The patient room must be set up according to St Jude’s Environmental Health and Safety policy prior to the administration of Ribavirin. Room preparation is to be done by the nursing staff. *See procedure section below https://home.stjude.org/ehs/Pages/ribavirin-precautions.aspx • Negative pressure room is mandatory for Ribavirin administration. • Preparation of the room is the responsibility of the nursing staff. • Ribavirin will be delivered from pharmacy in primed Aerogen syringe set appropriate for use on the MedFusion 3500 syringe pump. • The syringe pumps will be used, maintained, and stored by the respiratory therapy department. • The PPE cart is the shared responsibility of the respiratory therapist who administers the first dose of ribavirin and the nursing coordinator for that area. • Proper sign including contact precautions and STOP will be shared responsibility of the nursing and respiratory care. • All instances of spilled or leaked ribavirin must be documented in the event reporting system. • Ribavirin may be delivered to a patient during mechanical ventilation in a very specific set of circumstances. The final decision on the use of ribavirin is at the discretion of the ICU physician on service. EQUIPMENT: • Negative pressure room • DeMistifier 2000 HEPA filtration system. • DeMistifier negative pressure bed enclosure with canopy. • MedFusion 3500 Syringe pump • Flowmeter • Aerogen vibrating mesh nebulizer • Delivery Supplies (O2 tubing, O2 reducer, large bore tubing, T adaptor, and aerosol face mask) • Prescribed medication • STOP sign for the door during drug administration PPE • N95 or Positive Air Pressure mask required • Chemo resistant Gown • Double Gloves • Shoe covers PROCEDURE: 1.
    [Show full text]
  • IFU for Bioglue Surgical Adhesive (Outside USA)
    Instructions for Use Syringe BioGlue® Adhésif BioGlue® Collante Chirurgico Adhesivo Quirúrgico Chirurgical Mode Chirurgischer Klebstoff BioGlue® Istruzioni d’uso BioGlue® Instrucciones d’emploi Seringue Gebrauchsanwei sung Siringa de Uso Jeringuilla Spritze BioGlue® Adesivo BioGlue® Kirurgisk BioGlue® Kirurgisk Lim BioGlue® Vävnadslim Cirúrgico Instruções de Klæbemiddel Bruksanvisning Sprøyte Bruksanvisning Spruta Utilização Seringa Brugsanvisning Sprøjte Χειρουργική συγκολλητική BioGlue® Cerrahi Chirurgické adhezivum BioGlue® ουσία BioGlue® Οδηγίες Yapışkan Kullanım BioGlue® Návod k použití Chirurgische Kleefstof χρήσης Σύριγγα Talimatları Şırınga Stříkačka Gebruiksinstructies Spuit Chirurgické Lepidlo BioGlue® Sebészi Klej Chirurgiczny Хирургический клей BioGlue® Návod na Szövetragasztó BioGlue® Sposób Użycia BioGlue® Инструкция по Použitie Striekačka Használati útmutató Strzykawka применению Шприц Fecskendő CryoLife, Inc. 1655 Roberts Boulevard, NW • Kennesaw, Georgia 30144 • USA • +1 (770) 419-3355 • Fax +1 (770) 590-3753 http://www.cryolife.com 25°C 0°C L6313.009 Rev (07/2010) ENGLISH PRODUCT DESCRIPTION BioGlue® Surgical Adhesive is composed of bovine serum albumin and glutaraldehyde. The product’s two components are mixed within the applicator tip of the syringe during application to tissue. Polymerization of the surgical adhesive begins immediately upon application, reaching bonding strength within 2 minutes. INDICATIONS • Do not peel away BioGlue from an unintended site, as 3. While firmly grasping the syringe, nose upward, BioGlue Surgical Adhesive is indicated for use as an this could result in tissue damage. turn the cap 90° counterclockwise and remove the adjunct to standard methods of surgical repair (such • An animal study12 has shown that the circumferential cap by rocking it from side-to-side. Align the tip with as sutures, staples, electrocautery, and/or patches) to application of BioGlue restricts dilatation on growing the syringe using the corresponding notches on bond, seal, and/or reinforce soft tissue.
    [Show full text]
  • Instructions For
    Instructions for Use Please see page 2 Instructions for Use Please see page 3 SIMPONI® (SIM-po-nee) (golimumab) SIMPONI® (SIM-po-nee) (golimumab) SmartJect® autoinjector Prefilled Syringe SINGLE-DOSE Important Important If your doctor decides that you or a caregiver may be able to give your SIMPONI® injections at home, you should SIMPONI® comes as a single-dose prefilled syringe containing one 50 mg or one 100 mg dose. Each SIMPONI® prefilled receive training on the right way to prepare and inject SIMPONI® using SmartJect®. syringe can only be used one time. Throw away (dispose of) the used prefilled syringe (See Step 3) after one dose, even Do not try to inject SIMPONI® yourself until you have been shown the right way to give the injections by your doctor if there is medicine left in it. Do not reuse your SIMPONI® prefilled syringe. or nurse. If your healthcare provider decides that you or a caregiver may be able to give your injections of SIMPONI® at home, Please read this Instructions for Use before using SIMPONI® SmartJect® and each time you get a refill. There may be you should receive training on the right way to prepare and inject SIMPONI® using the prefilled syringe before new information. This leaflet does not take the place of talking with your doctor about your medical condition or attempting to inject. Do not try to inject yourself until you have been shown the right way to give the injections by your your treatment. healthcare provider. Read this Instructions for Use before using your SIMPONI® prefilled syringe and each time you get a refill.
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • Nurseadviseerr201805.Pdf
    May 2018 Volume 16 Issue 5 Safety with nebulized medications requires an interdisciplinary team approach Consider implementing the following recom - ebulization of inhaled medications provides an excellent delivery route for mendations to reduce the risk of errors with the treatment of both pulmonary and nonpulmonary conditions. The mist is nebulized medications. Neasily inhaled by breathing normally, without requiring coordinated breaths to inhale the medication (as required with metered dose inhalers). This delivery Communicate orders. Establish a reli - method generally provides a rapid onset of drug action, and minimizes systemic ef - able system for communicating new and fects. An additional advantage is that the nebulizer is adaptable and can be used changed orders for nebulized medications with a mouthpiece, adult or pediatric face mask, tracheostomy collar, T piece, or to respiratory therapy staff. Test the system ventilator circuit. before use, monitor its reliability, and inves - tigate all failed communication of orders to Unfortunately, there can also be errors with nebulized medications that are linked to determine opportunities for improvement. a wide variety of common system failures and human factors. However, review of errors reported to the ISMP National Medication Errors Reporting Program (ISMP Collaborate on assessments. Consider MERP) and other sources during 2016 and 2017, revealed patterns among error types collaboration between nursing and respi - and causative factors that were relatively unique to nebulized medications and/or ratory staff to determine if a dose of neb - the conditions under which they are prescribed, dispensed, and administered. ulized medication should be held based on an assessment of the patient. Deter - Omissions due to unavailability of respiratory therapist or failed communication mine conditions that require prescriber By far, the most frequently reported errors related to the use of nebulized medications notification of a held nebulizer treatment.
    [Show full text]
  • Medfusion® 3500 Syringe Infusion Pump with Pharmguard® Medication Safety Software
    Medfusion® 3500 Syringe Infusion Pump with PharmGuard® Medication Safety Software Smart and simple with added safety The Department of Health estimates we will be facing a shortage of over 800,000 nurses by the year 2020.1 Current shortages are having serious effects on day-to-day healthcare, and many nurses feel overworked and stressed – a situation that may lead to medication errors. The Joint Commission estimates 25% of hospitalized patient deaths are related to nurse understaffing.2 The dangers of medication errors n As many as 19 patients die every day from ® MR Conditional: The Medfusion pump may be used in static 3 magnetic fields up to 150 Gauss when secured to a non-movable medication errors in the United States object. Tested using 1.5 Tesla 64MHz shielded MRI system. n More than 770,000 injuries and deaths are due to preventable drug errors, which cost 3 hospitals up to $5.6 million per year n 61% of serious and life-threatening errors 3 are associated with infusion therapy n Infusion devices account for up to 35% of all medication errors, with 67% due to 4 programming errors n 38% of medication errors occur during the administration process; 51% harmed 5 the patient 1 National Center for Workforce Analysis, U.S. Department of Health and Human Services 2 The Joint Commission, 2002 3 Materials Management in Health Care, Oct. 2005 4 Tourville, 2003 5 JAMA, 1995 The total solution Post-occlusion bolus reduction ® The Medfusion syringe pump removes the possibility of a safety system has been the leader patient receiving an automatic bolus following an occlusion in infusion pump technology for over 15 years.
    [Show full text]
  • New Autoinjector Technology for the Delivery of Subcutaneous Methotrexate in the Treatment of Rheumatoid Arthritis
    Expert Review of Medical Devices ISSN: 1743-4440 (Print) 1745-2422 (Online) Journal homepage: http://www.tandfonline.com/loi/ierd20 New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis Michael Schiff, Jonathan Jaffe, Bruce Freundlich & Patrick Madsen To cite this article: Michael Schiff, Jonathan Jaffe, Bruce Freundlich & Patrick Madsen (2014) New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis, Expert Review of Medical Devices, 11:5, 447-455, DOI: 10.1586/17434440.2014.929492 To link to this article: http://dx.doi.org/10.1586/17434440.2014.929492 Published online: 17 Jun 2014. Submit your article to this journal Article views: 112 View related articles View Crossmark data Citing articles: 1 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierd20 Download by: [Rosa Weiss] Date: 14 February 2017, At: 10:26 Device Profile New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis Expert Rev. Med. Devices 11(5), 447–455 (2014) Michael Schiff*1, Methotrexate (MTX) is the cornerstone of treatment for rheumatoid arthritis (RA), and is Jonathan Jaffe2, widely used both as first-line therapy and as an important component of long-term therapy. Bruce Freundlich3,4 Although subcutaneous MTX is typically delivered orally, parenteral administration offers benefits with respect to tolerability and systemic exposure, and may be an underutilized and Patrick Madsen5 treatment option. The RA patient population presents specific challenges for safe and 1 Department of Rheumatology, accurate administration of parenteral therapies, because of common symptoms of joint pain University of Colorado, Denver, CO, USA and limited manual dexterity.
    [Show full text]
  • From Syringe to Autoinjector
    Volume 40 Number 6 Blow-Fill-Seal Data Integrity Using Modular JUNE 2016 Volume 40 Number 6 PLUS: Technology Training Construction PHARMACEUTICAL TECHNOLOGY From Syringe to JUNE 2016 2016 JUNE Autoinjector Building a Better Self-Injection Solution PharmTech.com PEER-REVIEWED Qualifying Personnel to Visually Inspect Cleaned Equipment, Part II SINGLE -USE SYSTEMS FORMULATION API SYNTHESIS & MANUFACTURING Integrating Single-Use Systems Customizing HPMC Adoption of Continuous Processing Advancing Drug Delivery Through Superior Polymer Design Safe and effective delivery of today’s complex drug molecules is increasingly a function of collaboration between polymer experts and pharmaceutical product development teams. Acting on enabling science, producing superior polymer excipient technology, and creating systems for optimum bioavailability, Ashland works alongside formulators to advance drug- specific delivery platforms. Explore how you can solve intricate drug formulation and development challenges with polymer expertise from Ashland. Visit us at Ashland.com/pharmaceutical Come visit us at Booth 610 Ashland [email protected] www.ashland.com/pharmaceutical ®Registered trademark, Ashland or its subsidiaries, registered in various countries ™Trademark, Ashland or its subsidiaries, registered in various countries ©2016, Ashland AD-13475.1 “Off-the-shelf solutions? No thank you. After all, our customers are something special.” Daniel Drossel Mechanical Engineering Technician (Design department) Each customer has its very own special requirements. That’s why we, at Optima, manufacture fi lling lines that are fi ne-tuned to our clients’ particular needs while off ering the benefi ts of an integrated and complete line: The complete machine package including high-precision functionalities, backed by consistent documentation and supported by an optimized and tailored software solution – in addition to a central point of contact who is passionate about your every concern… We are experts in special solutions, after all.
    [Show full text]